Covid 19 Research using Clinical Trials (Home Page)
Intervention-EDI and health coachingWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug760 | Diagnostic test for SARS-Cov2 for patients and health staff Wiki | 1.00 |
| drug644 | Control-EDI Wiki | 1.00 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051436 | Renal Insufficiency, Chronic NIH | 0.58 |
| D007674 | Kidney Diseases NIH | 0.45 |
| D002908 | Chronic Disease NIH | 0.32 |
| D006973 | Hypertension NIH | 0.28 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.58 |
| HP:0000077 | Abnormality of the kidney HPO | 0.45 |
| HP:0000822 | Hypertension HPO | 0.28 |
There is one clinical trial.
Clinical Trials
1 Controlling Hypertension Through Education and Coaching in Kidney Disease
Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.
NCT04087798 Chronic Kidney Diseases Chronic Disease Chronic Kidney Disease, Stage 3 (Moderate) Chronic Kidney Disease, Stage 4 (Severe) Chronic Kidney Disease Stage 5 Behavioral: Control-EDI Behavioral: Intervention-EDI and health coaching MeSH:Kidney Diseases Renal Insufficiency, Chronic Hypertension Chronic Disease
HPO:Abnormality of the kidney Chronic kidney disease Hypertension Nephropathy
Primary Outcomes
Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Systolic Blood Pressure between baseline and 12 months Time: Baseline, 12 months
Secondary Outcomes
Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Diastolic Blood Pressure between baseline and 12 months Time: Baseline, 12 months
Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of systolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 months
Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of diastolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 months
Description: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.
Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS) Time: Baseline up to 12 months
Description: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.
Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R) Time: Baseline up to 12 months
Description: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.
Measure: Morisky Medication Adherence Scale (MMAS - 8) Time: Baseline up to 12 months
Description: Length of time provider spends with the patient. This will be compared between the intervention group and control group.
Measure: Visit Time with provider Time: Enrollment visit (baseline)
Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.
Measure: Total time in clinic Time: Enrollment visit (baseline)
Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.
Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) Time: Baseline up to 12 months
Description: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT) Time: Baseline up to 12 months
Description: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree.
Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.
Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM) Time: Baseline up to 12 months
Description: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.
Measure: Perceptions of health coaching for the intervention group Time: Baseline up to 12 months
Description: The EMR will be reviewed to evaluate the patients medication refills for adherence.
Measure: Medication adherence from the electronic medical record (EMR) Time: Baseline up to 12 months
Description: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.
Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) Time: Baseline up to 12 months
Description: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.
Measure: Self-reported Blood Pressure-Related Behaviors Survey Time: Baseline up to 12 months
Description: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.
Measure: Provider Adoption based on EMR query and patient survey Time: Baseline
Description: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.
Measure: Provider Fidelity measured by EMR query Time: Baseline
Description: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.
Measure: Provider Perception of Usefulness by provider survey Time: Baseline up to 12 months
Description: Change in Serum Creatinine between baseline and 12-months
Measure: Change in serum creatinine Time: Baseline, 12 months
Measure: Change in urine protein-creatinine ratio Time: Baseline, 12 months
Measure: Change in estimated glomerular filtration rate (eGFR) Time: Baseline, 12 months
Related HPO nodes (Using clinical trials)
HP:0000077: Abnormality of the kidney
Genes 1719
WT1 SMARCAL1 SLC34A1 SDCCAG8 KCNJ1 MICOS13 INSR ELP1 IL17F AMMECR1 KCNAB2 NF1 STIL CASP10 KCNJ11 CC2D2A GPR35 MYLK TMEM138 DYNC2LI1 RAG2 SLC9A3R1 NSD1 CYP11B2 GNA11 KRT17 SF3B4 GLA WDR35 CC2D2A CCR1 CEP41 CCR6 NDUFS3 NUP133 ANOS1 PIK3CA MOCOS INS GBA CDK6 CFI FGFR3 TRNT XRCC4 CLCNKB BSCL2 PIEZO2 BCOR LMNB2 IFT43 PHYH SLX4 DICER1 INSR OCLN KMT2D NUP93 BBS4 ABCG8 BUB3 DHODH LRP5 AQP2 ATRX AKT3 SCARB2 ABCA12 GLA FANCI FGFR1 BRF1 RAI1 RAB18 FOXF1 EDNRB CLCN5 FLRT3 SLC25A11 EVC2 SI TBC1D20 DICER1 WNT4 DICER1 WT1 NUP133 PHC1 SOX9 FGF8 SALL4 LZTFL1 LTBP4 IFT80 UFD1 NDUFAF3 TDGF1 TMEM126B SDHD SEC61A1 LPIN2 IRF5 PTPRJ FANCE KITLG WIPF1 DLST COX6B1 HBB GANAB PKHD1 FGFR2 DCC COX14 ATP7B EP300 POU3F4 FREM1 SLC5A2 COL4A3 KIF14 EXTL3 DEAF1 COL4A3 PYGM WDPCP SLC34A1 HESX1 PIGP WAS ZFP57 IL23R FANCL CFH DIS3L2 PEX12 NCAPD3 DCHS1 ITGA3 SMAD4 MAFB NDUFV1 CFH PEX5 USP8 PCK1 TGM1 CFHR1 CREBBP PLG PKD1 PREPL IRAK1 ATRX ND6 AKT1 DNMT3A NSD2 C8ORF37 PEX2 MAD2L2 WDR19 PPP2R1A FOXP3 APC TRNL1 NODAL MSH6 DYNC2H1 KCNA1 PRDX1 PEX13 SMARCE1 ALPL NEK1 MEOX1 NDUFB3 PBX1 KCNJ10 CDKN1C PTEN RFWD3 PIGN PIGT KCNQ1OT1 COL5A2 NDUFAF3 H19 LEMD3 FGA PYGL MITF CHRM3 FAT4 TAPT1 MMUT DLL1 C3 KIF1B PALB2 NDUFS7 PDE6D SDHD CAMKMT WNT4 ACSL4 RTTN VHL ABCC8 KEAP1 SC5D SDHB STXBP1 STRADA EIF2AK3 NPHP3 MKKS FKRP ABCC6 TACO1 MCPH1 NEK8 SMARCD1 TRNF ALMS1 C1QA CDK5RAP2 TRPC6 CCDC28B ND3 PIGL C4A AVPR2 APOE AURKA AMER1 VHL FGFR3 CYP4F22 PRDM16 MRPS22 AP2S1 TP53 SLC7A9 ITGB4 COLEC11 PRKCSH APRT GDNF MBTPS2 RREB1 IFT140 TMEM237 CAD TSC2 NPHP3 PAH C1QBP WASHC5 SCN2A PC TMEM216 CYB561 TMCO1 MMUT PEX19 CFTR NDUFS1 ITGA2 NXN BBS12 LMOD1 MKS1 COL4A3 SOX10 NUP205 ZBTB16 COA8 SRY DYNC2I1 KCNJ11 FLT1 SMARCB1 RECQL4 PPP2R3C WT1 POR FAS MMACHC MBTPS2 DISP1 ROBO2 PDGFRL AXIN2 FLNA PTPN22 ASPM NRAS KYNU NAA10 TLR2 CENPF CCBE1 CDC73 WT1 GATA4 WDPCP SLC2A9 F8 FGFR2 TREX1 UBR1 GBA EBP KCTD1 TRIM28 GP1BB BBS12 SBDS SLC12A3 MAP11 REN TNXB RAD51 EMP2 NRIP1 ATN1 COL4A4 HNF1B PEX11B KLLN WT1 FH SLC17A5 ADAT3 C3 LIG4 TRNS1 IFT27 INPP5E FGFR2 EXT2 KYNU MAP2K2 UMOD APC CLCNKB ESCO2 CDC73 BRAF STAT4 PALB2 BBS7 PIGO HRAS SNAP29 TBX22 COL4A1 PLCD1 ADAMTS3 PIGL RAD51C CDH23 NDUFS4 FOXC2 LMNA SDHB SOX9 CDC42 GLMN SLC3A1 TBX1 CD96 DPH1 PTPN12 OFD1 RPGRIP1L SETD5 CCDC22 APPL1 COL14A1 IL2RG COQ8B ALOX12B ND4 WDR19 SLC6A17 PIGW SERPINF2 HELLPAR HNF1A NR0B1 DMRT3 PEX6 COPB2 NDUFB9 WDR19 ITGA8 HLA-DRB1 TRNV NPHP4 CD46 HPRT1 TP63 IFT172 CACNA1D WDR19 BUB1B RPL11 WNT4 CCN2 FAT4 SLC30A9 ANTXR1 SLC34A3 KDM6A CFHR3 OSGEP NUBPL SMS DYNC2LI1 PIGY TMEM231 LIMK1 GRHPR MINPP1 PDX1 LPIN1 NARS2 MAGI2 AFF4 LYZ NPHP4 AMMECR1 ARL6 ELN NADK2 NUP160 CEP55 IFT27 POLE H19 GBE1 TSC1 FUT8 ALDH18A1 HABP2 TBX1 SALL4 WDR4 SAA1 ADGRG2 UMOD NSDHL ZNF592 CEP135 KANSL1 NDUFV2 KNL1 ERCC8 PLG ROR2 HMGA2 GPC4 TRNQ XYLT2 NLRP3 KMT2A DSTYK ITGA8 FOXI1 CA2 WDR4 MYD88 LMAN1 LRP2 PEX1 DZIP1L GCM2 NDUFB10 SIX3 FRAS1 GP1BB CORIN AGGF1 RPGRIP1L NOD2 NUMA1 RERE UQCC2 H19-ICR MASP1 B9D1 CTU2 AGTR1 FANCB SLC1A1 FIBP PIK3CA UBR1 TRIM28 FOS PTPRO CCDC141 WT1 CPLANE1 PUS3 PAX2 CCDC141 PTPN22 RAI1 SPP1 ARMC5 IGF2 LEMD3 TRAF3IP1 HLA-DPB1 TMEM216 DHDDS MEN1 LMX1B TRNS1 CSPP1 TMEM216 TRNH PIGV HGD PEX14 IL12A WT1 ERCC4 DMXL2 FCGR2B REST SGPL1 MOCS2 CAV1 CC2D2A BBS10 SRP54 DHCR24 ABCC8 ARNT2 PCK2 BBS9 CD2AP DNASE1L3 NABP1 PDE6D HPSE2 AR ALG1 SKIV2L COA3 G6PC CFI PDGFRB INF2 ENPP1 NEUROD1 LZTFL1 ARL6 C1QC UMPS DNAJB11 CTNS BRCA2 CEP55 STXBP1 NELFA CD151 COX1 TBX1 TBL1XR1 CCND1 NSUN2 PAX2 TRRAP RPGRIP1L RAD51C LMNA BRCA1 ATP7A PRTN3 CSPP1 WDR35 ZEB2 HOXD13 TCTN2 SNAI2 SASS6 ALMS1 ETFDH ELN FGFR2 PLVAP PNPLA6 SULT2B1 F10 SON WDR19 NUP107 FAT4 LCAT KCNQ1OT1 FGF17 PIK3C2A CAV1 STRA6 IL17RA COQ6 CDKL5 NSD1 BUB1 YAP1 ARL6 ABCC6 COX2 WNT4 RET STOX1 COX20 HPRT1 USP9X INTU HDAC4 SPECC1L PPM1B IARS1 CTNS PEX3 MGME1 FAS CCND1 H19-ICR ARX ODC1 HNF1B PEX2 HSD11B2 SON NPHP1 RAG1 PRCC CEP120 SCO1 PHGDH G6PC3 SLC36A2 FGFR1 IFT80 SEC63 RBM8A MYMK GDF6 MAP3K1 SRCAP CPT2 MDM2 WWOX RAB3GAP2 HOGA1 MYH11 PET100 GLI3 PML SLC29A3 GP1BA WDR11 SCNN1B HSPG2 FBLN5 SCNN1B TMEM231 ZNF148 FRAS1 BLK SDHC SEMA3E FANCF IFT140 TBX3 KCNJ10 CHD7 CC2D2A SHH TCTN2 LMX1B CPT2 CEP290 ZIC2 MYO5B PGK1 PLEC KAT6A VDR CCND1 FANCG PPP3CA FUZ NIPBL YY1 IL7R ITGA2B FBN1 COQ7 CDKL5 NLRP3 KIAA0753 APOE ALDOB LETM1 INS FANCI PIGN GABBR2 APC2 EYA1 PIGA ACP5 ZAP70 TPRKB BUB1 MCM5 TMEM231 EPAS1 SPECC1L TFE3 SIX5 RPGRIP1L TRIM8 ASXL1 ETFA SF3B4 ALOXE3 PKD2 TRNN SMO TSC2 FGF10 BAX THOC6 TRAF3IP2 CLCN5 CEP290 ZNF423 DPF2 RPGRIP1L VPS33A NOTCH2 SLC4A4 DACT1 KLLN GANAB INPP5E WT1 PRKAR1A LMX1B CEP83 LRP4 WDR62 ANKS6 WAS OCRL CASP10 PIGT CA2 DHCR7 B9D2 RASGRP1 POGZ ANTXR1 LDLRAP1 IGF2 TMEM67 TMEM237 KIF7 EHMT1 KIAA0753 GNB1 MLH3 NOTCH3 DACT1 HNF4A INVS PQBP1 SLC3A1 FLCN ITGB4 VIPAS39 RARB CEP290 GRIP1 GLI2 WDR73 TMEM127 KAT6B BBIP1 AAGAB PACS1 PIK3CA TP53RK NDUFAF1 FBXL4 PEX13 COL1A1 FLNA HMBS TREX1 DNASE1 NOTCH2 MAX WT1 GPC3 VAC14 KIF1B USF3 DNAJC21 CCNQ USP9X BBIP1 NBN CWC27 PEX3 C1QB CHD7 CD109 EIF2AK3 ENG TKT MBTPS2 CLEC7A APC TALDO1 BSND RPL26 CIT TRIP11 USP8 WDR73 PGM3 FGFR1 FLNA SOX18 GNB1 PROKR2 KMT2D GATM FGFR3 GLI3 BCS1L HAAO TSC2 LRP4 POMT1 FAN1 B4GAT1 ARID1B PTEN STK11 CLCN5 SOX9 GPC3 MEFV OSTM1 CTLA4 BRIP1 INSL3 HOGA1 ATRX GATA3 MED25 TTC37 SALL4 YAP1 FXYD2 CHD7 MTRR PEX1 REN ND4 GPC3 MSH3 NCAPG2 STX3 TRIM32 CFH GRHPR TCF4 ALG8 BCOR TRNK NPHS1 CFI SLC7A7 HRAS SETBP1 IRF2BP2 RAI1 SLC35A2 SLC37A4 TFAP2A PTCH1 SEMA3E PIGQ CHST14 RPGRIP1 CEP120 XDH PDSS2 KCNH1 GALNT3 CLDN16 PEX10 ESCO2 NUP107 WT1 WRN DVL1 GCM2 COX8A BRAF NRAS POU6F2 RAD21 C4A MNX1 CEP290 GREB1L IL6 FLCN INF2 CTNNB1 SLC25A20 FANCA DSTYK KLHL7 RET WFS1 MST1 PEX12 DSE NDUFS6 NPHS2 SLC2A2 MET RAB23 GEMIN4 SCNN1A XRCC2 KISS1R TMEM67 WDR19 OFD1 FAM20A NTNG1 B2M CRTAP OCRL PIK3R2 WNT5A ALX4 AGPAT2 HSD17B4 DCLRE1C NPHP1 PMM2 GTF2IRD1 ND5 NDUFS8 FANCB FAS GPKOW SLC22A12 PIGY CEP57 FANCM LDLR ERCC6 CPT1A GPC4 CTLA4 MUC1 HPSE2 DIS3L2 OFD1 SDHB CLIP2 GCK COG6 COMT POR DCDC2 SFTPC XYLT1 STAT4 SLC4A1 GP1BA RMRP SLITRK6 GLIS3 SIX1 ERAP1 MAFB NDUFS2 ENPP1 BICC1 CFHR5 PDSS2 HIRA DKC1 TBCK AKT1 NPHP1 PAX6 SRY WFS1 GNAO1 TMEM107 PGAM2 SEC23B DYNC2I2 CHRM3 CYP24A1 KIF14 MDH2 GSN PLA2G2A TBC1D24 HLA-B CYTB WNT3 MKS1 TTC8 PROKR2 TRNL1 SLC6A20 PAX4 IQCB1 MEFV TMEM67 BCS1L PLAGL1 PRKCD HNF1A ADAMTS13 ND3 ARL3 CEP164 SLC12A1 STRA6 ND6 CLDN19 KMT2A COL4A1 RPS26 TTC21B ACTG2 AGXT LAMB2 CILK1 BBS10 MKS1 ARID2 SLC7A7 KCNQ1 EYA1 GCK ERBB3 ACTN4 IFT122 ADA2 FGFR2 SRC PMM2 RET TRNL1 HDAC8 LIPN THOC6 SDR9C7 PIK3CA DHCR7 RAB3GAP1 TREX1 IL17RC NPHP1 IFT172 NDUFB8 VHL TCTN3 RECQL4 PEX16 MITF SETBP1 KRAS TFAP2A CLCNKA ATP6V0A4 CPLANE1 RNU4ATAC ZIC3 B3GLCT RAI1 SALL1 CDKN1B F2 BBS5 PUF60 GREB1L DHX37 ND1 SDHD SLC26A4 TXNL4A HS6ST1 MSH2 ALDOB TRNE ND1 LAGE3 COQ2 HNF1B ATP1A1 LMNA COX10 MKKS THBD F5 LRIG2 TRIM37 HLA-DRB1 ALG9 FOXE1 FANCC H19-ICR SLC6A19 LIG4 TCTN3 COG1 MAP3K7 TBX15 H19 CFB MECP2 MFSD2A FANCB HNF4A PKD1 FANCD2 LARGE1 ADCY10 ZIC3 ADA PLCE1 CEP63 B9D1 BAZ1B TRNS2 PAFAH1B1 PCSK9 BCOR LRP5 CLCNKB FREM1 POMT2 DYNC2LI1 SMOC1 APRT COL4A5 SDHD ARX COA8 ITGB3 ACTG1 CLPB FLCN CAVIN1 PIGA FLNA ARID1B NPHP4 JAG1 FAM20A MMUT FAH ZNF423 STAT1 IFNG SDCCAG8 TBX18 YWHAE MED25 FGFR3 DYNC2I2 GLIS2 HYLS1 TACR3 TTC21B RNU4ATAC NPHS1 PIGL NDUFA6 PIK3R2 AIRE SF3B4 NPHP3 MEFV PIGV FH DPH1 SMC1A PIK3CA KAT6B CEP164 HMOX1 MEFV PLCD1 PUF60 DIS3L2 BTNL2 SPART PGM3 DUSP6 KANK2 NDUFA1 PLD1 TBC1D24 CHD7 BBS1 NDUFA11 ALG9 CASR FLII JAM3 SMARCAL1 PNKP NSMF BBS1 EP300 LEMD3 GLI3 EXT2 TSC1 ARL6IP6 SERPINH1 AMMECR1 HIC1 C8ORF37 FOXF1 BAP1 NPHP1 GP1BB F8 GDF6 TRNK DYNC2I2 PEX7 GABRD ABCC6 AGPAT2 POU6F2 PEX10 WDR73 MARS1 CSPP1 FANCA ATRX CDC73 OFD1 CLDN19 KCNJ10 NUP133 SPINK5 SLX4 HPRT1 IFIH1 SNRPB PRKCD SETD2 RPS19 SCN1B FCGR2A LAGE3 SLC26A1 CTH FEZF1 TP63 CDC73 TMEM231 TTR PDX1 STS FANCL FGF20 SOX17 GNAS DDX59 STAT5B ND2 KLF11 ARX OCRL MAP3K7 COG7 PEX7 SIX5 APOA1 IL12A-AS1 FOXH1 CASR PORCN STAT3 KIF14 COL4A4 FGF8 DLC1 CTNNB1 TRNT1 IFT43 CDK4 FKTN ITGA6 AKT1 SOX11 PRKCSH DDX59 CLCN5 KLRC4 TRIP13 PIEZO2 EVC CRB2 PEX6 TELO2 AGXT LRIG2 IFT172 DNA2 HLA-B DCHS1 FIBP NOD2 CEP290 HPRT1 SHANK3 SCO2 NDUFS2 NDUFB11 SLC25A22 VPS33A HSPA9 ADCY10 TP53 FLI1 NF1 CD46 GPC4 LIPT2 TIMMDC1 NDUFAF8 RAD21 BRCA2 GAS1 TMEM70 FASLG COX3 FANCB STRADA FAM20C ROR2 SDHA SNRPB MCTP2 PIGN ARVCF KIAA0586 INVS OPLAH TGIF1 FOXRED1 PTPN11 IQSEC2 SKI SDHC VPS33B MAPKBP1 MKKS NDUFAF4 CEP290 CISD2 B3GLCT AQP2 ZAP70 UBE2T BNC2 NPM1 SMC1A PEX1 AVPR2 PPARG STAG1 TRIM32 CCND2 TTC21B RBM10 EFEMP2 PRODH PORCN FLCN MYH9 FREM2 PTPN22 RBM10 PREPL PHEX RET GSN RFC2 IQCB1 OGG1 DCC RAF1 TSC1 CCNQ NDUFAF3 FOXP1 SOX10 EYA1 ANOS1 ERCC4 PTPN11 BBS2 VAMP7 CASR JMJD1C VANGL1 GRIA3 HBB MAFB NLRP3 PKD2 OSGEP FLNA TRIP13 SIX1 CACNA1S CENPJ PAX1 CDKN1B NAA10 TMEM126B ND5 NFIA SDHB BUB1B CLDN10 ATP6V1B1 EPG5 EHMT1 BMPER SOX4 ELP1 NR5A1 MKKS YY1AP1 NDUFAF2 LMNB2 HNF1A ARID1A RNF139 TCTN3 BRAF AIP TMEM67 POLR3A CPT2 TRNW TBX1 SPRY2 CCBE1 CPT1A HNF4A PPP1R15B SLC4A1 TRAF3IP1 CEP290 TNXB TMEM67 SEC24C BSCL2 DYNC2H1 NEUROD2 CDKN1C ANKLE2 BMP4 MAX TMEM107 SPRY4 PRMT7 COL7A1 TPRKB GPC3 PGAP2 ALG8 TTC8 PAX2 RSPO2 FANCE SHANK3 NPHP3 NDUFAF5 TMEM237 NOTCH2 TMEM67 SMARCC2 SDHAF2 PEX19 CD81 CHST14 RFWD3 PGK1 WDR35 CTNS ZFPM2 SURF1 LHX1 TMEM127 CDON NIPBL HNF4A CHD4 PHYH ACE ENPP1 RRM2B SCARB2 COQ2 DYNC2I1 NPHP1 APOB PEX5 ACVRL1 INTS1 FLCN GDF3 FH IL17RD SLC34A1 HNF1B PEX26 TRIP13 NUP85 TP53RK BRCA2 ITGA2B RIPK4 FIG4 VHL SMC3 B9D2 MAGED2 ANLN CASK XPNPEP3 TTC37 ZNF687 RERE TMEM67 TAF13 KRAS NIPAL4 MLXIPL HOXA13 RBBP8 KCNJ11 FREM2 SALL1 ATP6 NUP107 LAMB2 IKZF1 UBAC2 RARA LMX1B APC TMEM138 AGT SSR4 TCN2 MAP2K1 CHN1 DGKE VHL ND1 SMARCA4 APOL1 FIP1L1 MOCS1 NPHP3 HLA-DPA1 NEK8 SHPK ABCC8 TLR4 DVL3 RMND1 ADA DMP1 DYNC2H1 WNT3 TMEM216 MLH1 COPA PKHD1 FANCD2 BICC1 CPT2 ETFB FAM149B1 TBC1D8B SC5D GTF2I GDF2 BMPER FLNA MCC STXBP1 DNASE1L3 KCNE5 PYCR2 IL10 METTL5 SHH CRB2 SLC37A4 PTCH1 SH2B1 IGF2 CDC42 REST STAT3 TMEM260 AHI1 PRPS1 GNA11 GLI1 COL5A1 CACNA1D PTPN22 BBS4 TRNW ABCG5 AFF4 SDCCAG8 FN1 WT1 ADAMTSL1 FN1 HPS1 PROK2 WASHC5 SERPINA1 ITPR3 CEP152 MYO1E SLC12A3 PHF21A CYP27A1 SLC3A1 HNRNPU BUB1B FANCC ITGB3 DLL4 RAD54B SIK1 TBL2 SDHB TMEM216 DZIP1L RYR1 FLNB KYNU RBM8A IGF2 CEL SDCCAG8 MME ND2 CC2D2A PTH1R ARHGDIA KCTD1 GATA3 SEMA3A GP9 KCNJ5 ACTG2 LDHA TMEM231 CASR UMOD SUFU SARS2 HYMAI FLNA FLNB HMGA2 KDM6A PGAP3 SCNN1G VHL MCFD2 ACTB PUF60 COL3A1 CD96 CIT HP:0012622: Chronic kidney disease
Genes 127
PAX2 NPHP4 JAG1 SEC61A1 WT1 TMEM231 SDCCAG8 IQCB1 BICC1 COL4A4 TMEM67 WT1 TSC2 FAN1 NPHP1 IFT172 TBC1D8B SGPL1 MAGI2 GANAB NPHP4 NPHP3 CLCN5 CEP83 OCRL MUC1 NEK8 KYNU GLIS2 NUP160 TRPC6 TTC21B COL4A3 PYGM DCDC2 GATA3 TMEM67 SH2B1 CFH INF2 SAA1 AHI1 PKD2 CEP164 CFHR5 DNAJB11 CTNS INVS ALDOB CLCN5 IFT140 CD151 LAGE3 AGXT TMEM126B PKD1 NUP85 RAD51C TP53RK CEP290 MMUT SLC7A7 FN1 CEP290 ANLN DSTYK GSN XPNPEP3 MYO1E COQ8B IFT43 COL4A3 NUP205 CLDN16 IQCB1 WDR19 WDR19 NUP107 TSC1 FLT1 NUP93 DZIP1L NUP107 LAMB2 CORIN TMEM67 NOD2 SPRY2 INVS ARHGDIA NPHS2 TRAF3IP1 WDR19 TTC21B STOX1 LAMB2 PLCE1 DGKE MAPKBP1 CEP290 APOL1 NPHP4 CTNS CLDN19 UMOD PUS3 PAX2 NUP133 SARS2 TRAF3IP1 NPHP3 WDR19 PKD2 APRT LZTFL1 BNC2 HNF1B COL4A5 ACTN4 IFT122 NPHP1 CLCN5 TPRKB NPHP1 REN OSGEP SOX18 Protein Mutations 1
C677T HP:0000822: Hypertension
Genes 411
PLIN1 SMARCAL1 LIMK1 SDCCAG8 ELP1 TSC2 FMR1 CPOX GNAS COX1 SH2B3 LYZ CLCN2 NF1 NOTCH3 ARL6 EDA2R ELN APOA1 CTLA4 CC2D2A MLX FGFR2 ADA2 TRNC MMP14 MTRR BANF1 GLA TRNK TRNL1 CCR6 GPC3 CYP11B2 ERCC8 TRIM32 CFH ACVRL1 COL3A1 LRP6 TRNK XYLT2 CFI CALR ITGA8 SLC37A4 SUGCT GBA NF1 CD46 WT1 WRN KLHL3 BBS4 THPO SDHA POU6F2 ABCG8 CORIN NFIX PDE8B NOD2 ARVCF INVS PRKAR1A RET GLA SLC25A11 SCNN1A TRIM28 TRNQ OFD1 B2M WT1 TNFRSF11B ARMC5 FGFR2 HLA-DPB1 PPARG EDA TP53 BNC2 ALX4 LMX1B NPHP1 ACAT1 ACTA2 GNAS GTF2IRD1 SDHC UFD1 ENPP1 GATA5 LEMD3 MYH11 HGD SDHD RET RFC2 IRF5 KCNJ5 LDLR ERCC6 DLST REST CAV1 GANAB BBS10 SMAD3 TET2 TRNW MUC1 POU3F4 OFD1 ADA2 SDHB ERCC4 BBS9 CD2AP LMNA CYP11B1 MEF2A MMP2 CLIP2 COL4A3 ELN COMT HPSE2 BBS2 XYLT1 PRKACA JMJD1C SMAD4 VANGL1 G6PC WNK4 DIS3L2 TMEM70 HBB ENPP1 MAFB LZTFL1 TRNS2 PKD2 USP8 HIRA TRIP13 DNAJB11 FBN1 TGFBR1 CFHR1 SH2B3 PKD1 LMNA PRKAR1A SDHB SCN2B PRTN3 NR3C2 WDR35 MDH2 DNMT3A ELP1 ALMS1 ELN TRNL1 IQCB1 RET MKKS YY1AP1 LARS2 AIP TBX1 TGFBR2 SPRY2 FBN1 NOTCH1 ABCB6 PRKACA MTTP MYLK ARL6 ABCC6 TRAF3IP1 COL5A2 RET STOX1 H19 LEMD3 FGA TMEM67 SEC24C MAX CYP11B1 SLC25A11 ND6 KIF1B ACTN4 ADA2 HSD11B2 DYRK1B NPHP1 BMPR2 PDE3A ND1 TTC8 JAK2 MGP NOTCH2 VHL SDHB SDHAF2 VHL MYMK NPHP3 ABCC6 TGFBR3 PPARG ALMS1 SMAD6 TRPC6 CCDC28B TMEM127 VHL TNFRSF11A SCNN1B BBS5 SCNN1B ARHGAP31 APOB SDHD SDHD PDE3A GDNF RREB1 CYP11B1 ECE1 TMEM237 TRNE SDHC FH YY1AP1 LMNA TGFB2 COX3 GPR101 CYP17A1 BRCA2 THBD LMX1B WNK1 LRIG2 FIG4 CEP290 HLA-DRB1 XPNPEP3 CCND1 MKS1 ACTA2 FUZ COL4A3 CYTB SMAD4 LMNA TRNV SLC2A10 FBN1 PRKG1 COQ7 MLXIPL KIF1B AIP FLT1 SERPINA6 CFB PLIN1 HLA-B NKX2-5 WT1 PKD1 EGFR MC4R EPAS1 SLC2A10 GCH1 BAZ1B NSMCE2 VHL PCSK9 KRT8 WT1 WDPCP TRNK PKD2 APRT HLA-DPA1 MPL COL4A5 KCTD1 SDHD TRIM28 GP1BB THSD1 BBS12 CEP290 FMO3 CYP21A2 CUL3 NPHP4 PKHD1 BICC1 COL4A4 BSCL2 NR3C1 WT1 GANAB C3 COX2 TRNF IFT27 GTF2I STAT1 SDCCAG8 PAM16 MFAP5 LOX IL12B SLC37A4 LDLRAP1 MYH7 BBS7 TGFB3 CBS ARMC5 CEP164 ADAMTSL4 INVS CDH23 COL5A1 CACNA1D LMNA PTPN22 SCNN1A SDHB ABCG5 TBX1 FN1 TMEM127 BBS1 CYP17A1 FN1 RPGRIP1L AIP PHF21A CACNA1H POR ND5 ENG BBS1 PDE11A EXT2 COL1A1 GUCY1A1 TSC1 FBN1 TBL2 HMBS HMBS C8ORF37 NR3C1 FOXF1 PRKAR1A NPHP1 CEP19 KRT18 MAX ABCC6 VAC14 KIF1B KCTD1 TRNS1 HSD11B2 GJA1 SCNN1G KCNJ5 BBIP1 PDE11A ANGPTL6 CDH23 KCNJ5 MAT2A SMAD4 IDUA IFT172 CACNA1D WDR19 ZMPSTE24 CYP11B1 FOXE3 CCN2 GNAS SCNN1G GUCY1A1 NFU1 VHL USP8 CFHR3 NOS3 COL3A1 JAK2 OSGEP HP:0000112: Nephropathy
Genes 118
PRODH DYNC2LI1 DYNC2H1 MYH9 FAM20A SEC61A1 TMEM231 TTR TMEM237 TREX1 WT1 PDX1 WIPF1 INPP5E WT1 LYZ CC2D2A KLF11 YWHAE WAS TRNF APOA1 TMEM138 ALG1 WAS SCNN1B TMEM237 WDR4 SAA1 DYNC2I1 GLA MAFB NEUROD1 UMOD NPHP1 COL4A1 MAFB ND1 ND4 OSGEP SLC26A4 NUP133 IFT140 CD151 BLK PAX6 COX1 CCND1 IFT140 IFT172 VIPAS39 WFS1 CEP290 KCNJ10 TRNW CC2D2A TRNQ RPGRIP1L ND5 WDR73 NLRP3 INS ND6 TP53RK FOXI1 APPL1 BSCL2 TMEM67 PAX4 NUP107 MEFV WDR19 KCNJ11 COX3 HIC1 HNF1A WT1 PRDX1 CAV1 RPGRIP1L NOD2 CEL MMACHC DYNC2I2 TPRKB SCARB2 HNF4A CLDN19 COX2 FGA VPS33B SCNN1A TRNS2 PAFAH1B1 FOS CISD2 WDR19 B2M EIF2AK3 HPRT1 GCK TMEM216 AGPAT2 LMX1B ABCC8 COL7A1 TRNS1 ADA2 IFT80 TRNL1 LAGE3 SCNN1G PPARG CAVIN1 TRNH ZNF423 CEP120 TTC21B Protein Mutations 0
SNP 0
Primary Outcomes
Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Systolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsSecondary Outcomes
Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Diastolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of systolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of diastolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.
Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS) Time: Baseline up to 12 monthsDescription: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.
Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R) Time: Baseline up to 12 monthsDescription: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.
Measure: Morisky Medication Adherence Scale (MMAS - 8) Time: Baseline up to 12 monthsDescription: Length of time provider spends with the patient. This will be compared between the intervention group and control group.
Measure: Visit Time with provider Time: Enrollment visit (baseline)Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.
Measure: Total time in clinic Time: Enrollment visit (baseline)Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.
Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) Time: Baseline up to 12 monthsDescription: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT) Time: Baseline up to 12 monthsDescription: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.
Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM) Time: Baseline up to 12 monthsDescription: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.
Measure: Perceptions of health coaching for the intervention group Time: Baseline up to 12 monthsDescription: The EMR will be reviewed to evaluate the patients medication refills for adherence.
Measure: Medication adherence from the electronic medical record (EMR) Time: Baseline up to 12 monthsDescription: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.
Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) Time: Baseline up to 12 monthsDescription: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.
Measure: Self-reported Blood Pressure-Related Behaviors Survey Time: Baseline up to 12 monthsDescription: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.
Measure: Provider Adoption based on EMR query and patient survey Time: BaselineDescription: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.
Measure: Provider Fidelity measured by EMR query Time: BaselineDescription: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.
Measure: Provider Perception of Usefulness by provider survey Time: Baseline up to 12 monthsDescription: Change in Serum Creatinine between baseline and 12-months
Measure: Change in serum creatinine Time: Baseline, 12 monthsMeasure: Change in urine protein-creatinine ratio Time: Baseline, 12 months
Measure: Change in estimated glomerular filtration rate (eGFR) Time: Baseline, 12 months